

# Portfolio Commentary

## Small Cap Growth

# Q4 | 2018

### MARKET REVIEW

Stocks experienced a difficult market in the quarter, with all major domestic equity indices posting large negative returns that erased the year's prior positive to-date gains. In this sharp market reversal, growth stocks suffered the greatest declines, and large caps proved more defensive than small caps. Small-cap growth stocks, as measured by the Russell 2000® Growth Index, fell 21.65%, suffering losses across most sectors, led lower by energy (-41.32%), materials (-25.51%), and healthcare (-25.05%). Only the utilities sector (+1.76%) avoided losses.

Broad volatility was escalated by mounting anxiety around slowing global growth, trade war tariffs, stumbling oil prices, and a flattening yield curve with the potential to invert, as investors seemed intent on finding growing signs of a possible U.S. recession. The selloff was a stark contrast to the investor enthusiasm in response to accelerating earnings and profits that had lifted growth stocks higher, albeit on a bumpier trajectory, for most of 2018.

### PERFORMANCE

For the quarter, the Small Cap Growth Composite returned -19.20% (gross)/-19.42% (net), outperforming the -21.65% return of the benchmark Russell 2000® Growth Index. For the full year, the Composite also outperformed, with a return of -5.55% (gross)/-6.49% (net) versus -9.31% for the benchmark. Stock selection in the healthcare, materials, industrials, and consumer staples sectors, an underweight position in energy, and an overweight position in information technology contributed positively to relative performance. Stock selection in the consumer discretionary sector and an underweight position in real estate detracted from relative returns.

Five9 and AMN Healthcare Services were among the strongest stock contributors to relative performance.

- Contact center software company Five9 began the quarter falling on broad technology sector weakness, but the shares sharply rebounded after the company reported stronger-than-expected earnings and attractive enterprise business growth. We continue to hold the stock on its positive fundamentals and upbeat earnings outlook.
- Nursing care staffing company AMN rose on better-than-expected earnings and the announcement that it had renewed and expanded its largest client, Kaiser Permanente. We maintained the position on the positive news.

### PORTFOLIO CHARACTERISTICS

	Portfolio	Benchmark
Wtd. Avg. Market Cap (\$b)	3.37	2.20
Price-to-Earnings*	23.21	17.53
Price-to-Book	3.93	3.35
Price-to-Sales	2.82	1.51
Std. Dev. (3 yr) (%)	15.53	16.46
Alpha (3 yr) (%)	-0.18	0.00
Beta (3 yr)	0.93	1.00
Std. Dev. (5 yr) (%)	15.45	16.16
Alpha (5 yr) (%)	-2.01	0.00
Beta (5 yr)	0.93	1.00
Est. 3-5 Yr EPS Growth (%)	12.87	17.49
Operating Margin (%)	5.16	7.86

\*P/E is calculated using forward 12-month earnings.

### TOP RELATIVE CONTRIBUTORS<sup>1,2</sup>

	Average Weight	Relative Contribution
Five Below, Inc.	0.13	0.15
Tandem Diabetes Care, Inc.	0.33	0.15
Air Transport Services Group, Inc.	0.91	0.11
Nutrisystem, Inc.	0.40	0.10
Dorman Products, Inc.	0.56	0.09
WD-40 Co.	1.20	0.08
AAON, Inc.	0.37	0.05
AMN Healthcare Services, Inc.	1.61	0.05
Five9, Inc.	1.77	0.05
Chart Industries, Inc.	0.33	0.02

### TOP RELATIVE DETRACTORS<sup>1,2</sup>

	Average Weight	Relative Contribution
Roku, Inc. Class A	1.31	-0.88
Sarepta Therapeutics, Inc.	2.06	-0.71
Neurocrine Biosciences, Inc.	1.35	-0.63
HealthEquity Inc.	1.96	-0.63
Encompass Health Corp.	2.21	-0.52
Balchem Corp.	1.88	-0.52
Il-VI Inc.	1.73	-0.49
Interxion Holding N.V.	2.33	-0.48
Dycom Industries, Inc.	1.33	-0.47
Bio-Techne Corp.	1.44	-0.46

Relative contribution: contribution to return relative to the benchmark, limited to stocks held in the portfolio.

### TOP 10 HOLDINGS<sup>1</sup> (% of portfolio)

Q2 Holdings, Inc.	2.93
Fair Isaac Corp.	2.73
Interxion Holding N.V.	2.44
Teledyne Technologies Inc.	2.43
Texas Roadhouse, Inc.	2.42
Five9, Inc.	2.22
Encompass Health Corp.	2.20
Mercury Systems, Inc.	2.17
Sarepta Therapeutics, Inc.	2.09
Chemed Corp.	1.96

Source: FactSet. All data as of 12/31/2018.

<sup>1</sup> See Holdings Disclosure on page 3.

<sup>2</sup> The contributors/detractors listed do not represent all securities purchased or sold for our clients. To obtain a list showing the contribution of each holding that contributed to overall performance during the quarter and the calculation methodology, please call 1-404-845-7640.

Roku and Neurocrine Biosciences were among the largest stock detractors from relative performance.

- Despite reporting strong revenues and gross profits, streaming-video company Roku fell as investors shied away from firms with riskier new business models amid the general stock market volatility. Fears of increased competition also weighed on shares, as did trade tariff concerns given that most of the company’s devices are manufactured in China. We took advantage of the lower price to slightly add to our position.
- Biopharmaceutical company Neurocrine Biosciences declined on news that its Ingrezza product failed to meet its primary goal of reducing tic severity in children and adolescents with Tourette syndrome during a Phase II clinical trial. We had trimmed the position prior to this setback announcement but still continued to hold the smaller allocation.

## PORTFOLIO CHANGES

During the quarter, we bought Tandem Diabetes Care and Five Below, and sold Nutrisystem and TopBuild.

- We took advantage of the market selloff to purchase medical device manufacturer Tandem Diabetes Care. The company makes insulin pumps, a product we believe offers tremendous growth potential as more diabetes patients move to this type of treatment rather than insulin injections.
- We took the opportunity to establish a new position in discount store Five Below, which offered an attractive valuation entry point as retail stocks widely fell during the quarter. The company has consistently reported strong unit growth and same-store sales comparisons, and we expect its business to continue to benefit from healthy U.S. employment.
- We sold weight loss firm Nutrisystem after the stock rallied on news that Tivity Health will acquire the company.
- We exited home insulation company TopBuild based on the cooling housing market as interest rates have moved higher.

## PERFORMANCE ATTRIBUTION (%) AS OF 12/31/2018

	Quarter-end Sector Weights		Impact		
	Portfolio	Benchmark	Sector Weight	Stock Selection	Total
Health Care	30.45	26.32	-0.16	1.01	0.85
Energy	0.51	1.72	0.39	0.06	0.45
Industrials	16.39	17.73	0.02	0.42	0.43
Materials	6.39	3.38	-0.13	0.47	0.34
Consumer Staples	2.74	3.11	-0.08	0.35	0.26
Information Technology	22.56	18.38	0.23	-0.04	0.18
Communication Services	2.48	3.44	-0.06	0.15	0.09
Utilities	0.00	0.52	-0.12	0.00	-0.12
Financials	6.64	7.47	-0.05	-0.15	-0.21
Real Estate	0.00	2.96	-0.28	0.00	-0.28
Consumer Discretionary	11.84	14.87	-0.04	-0.48	-0.53
<b>Total</b>			<b>-0.35</b>	<b>1.79</b>	<b>1.36</b>

Source: FactSet.

Performance attribution does not incorporate the effects of cash, unclassified securities or expenses and may change at any time without notice. The total impact may not equal the difference between Portfolio and Benchmark returns.

## OUTLOOK

Our outlook for growth stocks remains cautiously optimistic. The deteriorating risk sentiment that drove markets lower in the fourth quarter seemed to be stabilizing near year-end. Still, growth appears to be slowing. Housing, automotive sales, and inflation metrics have all begun to show small cracks, though not at levels that are necessarily indicative of any major problems—yet. Interest rates continue to normalize, and the cash boost gains from last year’s corporate tax cuts are also fading. On the global growth front, Europe remains weak and faces major uncertainties such as Brexit, and China continues to decelerate, further exacerbated by U.S. trade policy. While we believe further market gains are likely to continue, at this late stage of the cycle, it is crucial to pay even closer attention to fundamentals and really hone in on the individual securities best positioned to buck the overall slowing growth trend.

## PERFORMANCE COMPARISON (%) AS OF 12/31/2018

	QTD	YTD	1 Year	3 Year	5 Year	10 Year
Small Cap Growth Composite (Gross)	-19.20	-5.55	-5.55	6.57	2.71	12.64
Small Cap Growth Composite (Net)	-19.42	-6.49	-6.49	5.52	1.69	11.64
Russell 2000® Growth Index	-21.65	-9.31	-9.31	7.24	5.13	13.52
eVestment Alliance Small Cap Growth Median*	-20.75	-4.00	-4.00	9.52	6.42	15.09
# of Portfolios in Median Calculation	184	184	184	180	172	155

eVestment Alliance data capture date: 1/22/19

**Past performance is not indicative of future results.** This presentation is solely for SUPPLEMENTAL INFORMATION purposes, intended for institutional investor, and may not be provided unless accompanied or preceded by the fully compliant GIPS Composite Presentation. The comparative performance contained herein reflects annualized returns for specific time period, is not indicative of actual annual returns, and may not be relied upon for investment decisions. Complete information regarding Silvant's returns is included on the GIPS presentation on page 4. The performance inception date for the composite is 1/1/2001.

Russell 2000® Growth Index is composed of the securities found in the Russell 2000 Index with a greater-than-average growth orientation. Companies in this index tend to exhibit higher price-to-book and price-to-earnings ratios. Investors cannot invest directly in an index.

Frank Russell Company is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell® is a trademark of Frank Russell Company.

This information and general market-related projections are based on information available at the time, are subject to change without notice, are for informational purposes only, are not intended as individual or specific advice, may not represent the opinions of the entire firm, and may not be relied upon for individual investing purposes. Information provided is general and educational in nature, provided as general guidance on the subject covered, and is not intended to be authoritative. All information contained herein is believed to be correct, but accuracy cannot be guaranteed. This information may coincide or conflict with activities of the portfolio managers. It is not intended to be, and should not be construed as investment, legal, estate planning, or tax advice. Silvant Capital Management does not provide legal, estate planning, or tax advice. Investors are advised to consult with their investment professional about their specific financial needs and goals before making any investment decisions. Portfolio characteristics, sector analysis, and holdings exclude cash and may change at any time.

\*eVestment Alliance (eA) is a manager-reported database on hundreds of investment managers and thousands of investment products covering a full range of asset classes, investment styles, and geographic concentrations. Based on manager input, eA independently constructs universes using qualitative and quantitative factors. The investment products are organized into peer groups and assessed on an ongoing basis to ensure the consistency of a product's attributes within a designated style classification. In addition, eA utilizes style analysis tools, performance analytics, and the review of a product's investment strategy narrative in the construction of wide-ranging universes that are both pure in style and consistent over time.

The eVestment Number of Portfolios represents the number of investment products included in the calculation of the median return for the given eVestment universe for the given time period. Individual investment managers may have more than one investment product included in the universe, so the number of observations will likely be greater than the actual number of investment managers represented.

## HOLDINGS DISCLOSURE

The information provided in this report should not be considered a recommendation to purchase or sell any particular security. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that securities sold have not been repurchased. The securities discussed do not represent an account's entire portfolio and in the aggregate may represent only a small percentage of an account's portfolio holdings.

It should not be assumed that any of the securities transactions or holdings discussed were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the securities discussed herein.

## IMPORTANT RISK CONSIDERATIONS

**Equity Securities:** The market price of equity securities may be adversely affected by financial market, industry, or issuer-specific events. Focus on a particular style or on small or medium-sized companies may enhance that risk. **Growth Stocks:** Growth stocks are typically sensitive to market movements because their market prices tend to reflect future expectations. When it appears those expectations will not be met, the prices of growth stocks typically fall.

For information, contact:

Silvant Capital Management | 404-845-7640 | [www.silvantcapital.com](http://www.silvantcapital.com)

# Q4 | 2018 Small Cap Growth

SMALL CAP GROWTH COMPOSITE 1/1/01 – 12/31/2018

Year	Gross of Fee Return (%)	Net of Fee Return (%)	Benchmark Return (%)	Number of Portfolios	Composite Dispersion (%)	3-Year Standard Deviation		Total Composite Assets at End of Period (US\$ Mil)	Total Firm Assets (US\$ Mil)
						Composite	Benchmark		
2018	-5.55	-6.49	-9.31	Five or fewer	N/A	15.53	16.46	24	748
2017	15.88	14.74	22.17	Five or fewer	N/A	13.54	14.59	30	1,138
2016	10.60	9.50	11.32	Five or fewer	N/A	15.92	16.67	45	1,277
2015	-2.30	-3.27	-1.38	Five or fewer	N/A	14.62	14.95	70	1,382
2014	-3.35	-4.32	5.60	Five or fewer	N/A	14.00	13.82	246	1,736
2013	46.31	44.90	43.30	Five or fewer	N/A	17.18	17.27	301	2,233
2012	16.16	15.02	14.59	Five or fewer	N/A	21.34	20.72	353	3,002
2011	1.05	0.04	-2.91	Five or fewer	N/A	23.39	24.31	427	3,686
2010	25.34	24.14	29.09	6	0.32	26.35	27.70	537	4,093
2009	33.63	32.63	34.47	7	0.42	23.03	24.85	493	3,818
2008	-40.44	-41.44	-38.54	7	N/A	20.64	21.26	428	3,847

Silvant Capital Management LLC claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. Silvant has been independently verified for the period March 31, 2008 (the date of the Firm's founding) through December 31, 2017. A copy of the verification report is available upon request. Verification assesses whether (1) the firm has complied with all the composite construction requirements of the GIPS standards on a firm-wide basis and (2) the firm's policies and procedures are designed to calculate and present performance in compliance with GIPS standards. Verification does not ensure the accuracy of any specific composite presentation.

- Silvant Capital Management LLC ("Silvant") is an SEC-registered investment adviser and is a wholly owned subsidiary of Virtus Partners, Inc., a wholly owned subsidiary of Virtus Investment Partners, Inc. ("Virtus"). Registration of an investment adviser does not imply any level of skill or training. Silvant manages assets on behalf of institutional and retail separate accounts and mutual funds. Silvant became an affiliate of Virtus effective June 1, 2017, when Virtus acquired RidgeWorth Capital Management LLC and RidgeWorth Investments ("RidgeWorth"). Silvant was created March 31, 2008, when all of the investment decision-makers associated with the growth equity investment strategies of RidgeWorth became employees of Silvant. The staff and decision making process remained intact and independent within Silvant. For composite reporting purposes, the Firm is defined as all equity portfolios managed by Silvant. Composite performance results are linked to performance history generated at RidgeWorth.
- The Small Cap Growth Strategy composite includes fully discretionary separately managed investment accounts and registered and unregistered mutual funds managed in accordance with the small cap growth style, with the objective of investing in in stocks with a competitive advantage, strong profitability metrics, above average free cash flow, above average operating margins and positive price trends. Under normal circumstances, Small Cap Growth Portfolios will have at least 80% of their assets invested in common stocks and other U.S. traded equity securities of small cap companies. U.S. traded equity securities may include American Depository Receipts ("ADR's"). Silvant considers small cap companies to be companies with market capitalizations similar to those of companies in the Russell 2000® Growth Index. Silvant will seek out securities it believes have strong business fundamentals, such as revenue growth, improving cash flows, increasing margins and positive earnings trends. Prior to September 1, 2015, the gross of fee return for the mutual fund was calculated by adding back the fund's published total operating expense ratio to the net of fee mutual fund performance; we now use the gross of fee return of the underlying portfolio. A complete description of the composite is available on request.
- The registered and unregistered mutual funds were added to the composite effective April 1, 2008, immediately after the creation of Silvant Capital Management. Prior to that date the composite consisted of only separately managed accounts.
- The benchmark for the Small Cap Growth Strategy composite is the Russell 2000® Growth Index, which is composed of the securities found in the Russell 2000® Index with a greater-than-average growth orientation. Companies in this index tend to exhibit higher price-to-book and price-to-earnings ratios. The index is calculated on a total-return basis with dividends reinvested. Index returns do not reflect the deduction of any fees or expenses.
- The three-year annualized standard deviations for the composite and the benchmark index are calculated using monthly returns.
- Beginning March 31, 2008, composite policy required the temporary removal of any portfolio incurring a client initiated significant cash inflow or outflow of 10% or greater of portfolio assets. This policy was discontinued effective January 1, 2013.
- The dispersion of annual returns is measured by the equal-weighted standard deviation of portfolio returns represented within the composite for the full year. Partial year dispersion is measured by the equal-weighted standard deviation of portfolio returns represented in the composite for the partial year period specified. No dispersion is reported for periods with five or fewer portfolios (shown as N/A).
- Returns are calculated based on total return which (a) includes cash returns, realized and unrealized gains plus income; (b) utilizes trade date and accrual accounting; and (c) is after the deduction of actual trading fees and expenses. Portfolio returns are calculated utilizing daily valuation. Composite returns, calculated monthly, are the weighted average return of the underlying portfolios using beginning-of-period market values. Composite gross of fee returns do not reflect any deduction for investment advisory fees, custodial charges or other costs that a client might incur in connection with the management of an account. Composite net of fee performance is calculated assuming a fee of 1.00%, the highest fee for this type of investment account.
- The standard management fee schedule applicable to small cap growth equity accounts is as follows: 1.00% on the first \$10 million, 0.80% on the next \$40 million, and 0.60% on all over \$50 million. The minimum annual fee is \$10,000. Actual investment advisory fees incurred by clients may vary.
- This composite was created March 31, 2008, the inception date of Silvant, and continues the investment strategy of a composite originally created in 2001. The composite has performance history with an inception date of January 1, 2001.
- The minimum portfolio size for the Small Cap Growth Strategy composite is \$1 million. For further information on investment management fees, please refer to Form ADV Part 2.
- Policies for valuing portfolios, calculating performance, and preparing compliant presentations are available upon request.
- A complete list and description of firm composites and performance results is available upon request.
- Past performance is not indicative of future results and no investment is guaranteed for return of principal and/or return on investments. Results will vary among accounts. All information provided and used in calculations is believed to be correct, but accuracy cannot be guaranteed. Please consult with a financial professional before investing.